



World Health  
Organization

Stop TB Partnership



## Provisional list of participants

### 5th Annual Global Laboratory Initiative Meeting, Global Forum of Xpert MTB/RIF implementers, and Supranational TB Reference Laboratory Network Consultation

Les Pensières, Veyrier-du-Lac, France  
15 - 18 April 2013

**1. Eric Adam**

OTSUKA SA  
Rue Mont Blanc 7  
Geneva  
Switzerland  
[eadam@otsuka-sa.ch](mailto:eadam@otsuka-sa.ch)

**2. Tope Adepoiyi**

PATH  
455 Massachusetts Ave NW Suite 1000  
Washington  
USA  
[tadepoyibi@path.org](mailto:tadepoyibi@path.org)

**3. Dissou Affolabi**

Médecin Biologiste, Medical Officer, NTP  
au Laboratoire de Référence des Mycobactéries  
du PNT  
01 BP 817 - Cotonou  
Benin  
[affolabi\\_dissou@yahoo.fr](mailto:affolabi_dissou@yahoo.fr)

**4. Heidi Albert**

FIND  
36 Airlie Place  
Constantia  
Cape Town  
South Africa  
[Heidi.albert@finddiagnostics.org](mailto:Heidi.albert@finddiagnostics.org)

**5. Arike Alenova**

National centre for Tuberculosis Problem  
050010, Bekkhozina str. 5,  
Almaty,  
Kazakhstan  
[arika.alenova@mail.ru](mailto:arika.alenova@mail.ru)

**6. Heather Alexander**

Centers for Disease Control and Prevention  
1600 Clifton Road MS F08  
Bldg 17 Room 4020  
Atlanta, GA, 30322  
USA  
[HAlexander1@cdc.gov](mailto:HAlexander1@cdc.gov)

**7. Wimi Ambarwati**

Sub Directorate Microbiology and Immunology  
General Medical Care  
Ministry of Health Republic Indonesia  
Jalan H.R. Rasuna Said Kav.  
4 – 9 , Jakarta 12950,  
Indonesia  
[wiamiabar@yahoo.com](mailto:wiamiabar@yahoo.com)

**8. Valentina Anisimova**

KNCV Tuberculosis Foundation  
Nairobi  
Kenya  
[AnisimovaV@kncvtbc.nl](mailto:AnisimovaV@kncvtbc.nl)

**9. Uladzimir Antonenka**

SRL Gauting, IML red GmbH  
Robert-Koch-Allee 2  
82131 Gauting  
Germany  
[u.antonenka@asklepios.com](mailto:u.antonenka@asklepios.com)

**10. Elisa Ardizzoni**

MSF/Institute of Tropical Medicine  
Nationalestraat 155  
2000 Antwerp  
Belgium  
[eardizzoni@itg.be](mailto:eardizzoni@itg.be)

**11. Martin Baker**

Massachusetts Supranational Laboratory  
305 South Street  
Jamaica Plain  
MA 02130  
USA  
[Martin.baker@umassmed.edu](mailto:Martin.baker@umassmed.edu)

**12. Draurio Barreira**

NTP Manager  
SMLN M1 08 Con 06  
Caso 37  
Brasilia-DF  
Brazil  
[draurio.barreira@saude.gov.br](mailto:draurio.barreira@saude.gov.br)

**5th Annual Global Laboratory Initiative Meeting,  
Global Forum of Xpert MTB/RIF implementers, and  
Supranational TB Reference Laboratory Network Consultation**

**13. Jean Luc Berland**

Fondation Mérieux  
55 route d'Annecy  
74290 Veyrier-du-Lac  
France  
[jean-luc.berland@fondation-merieux.org](mailto:jean-luc.berland@fondation-merieux.org)

**14. Amy Bloom**

Senior Technical Advisor  
US Agency for International Development (USAID)  
BGH/OHIV/TLRD  
5.10.45, 5th Floor, RRB  
1300 Pennsylvania Ave  
USA  
[abloom@usaid.gov](mailto:abloom@usaid.gov)

**15. Catharina Boehme**

Foundation for Innovative New Diagnostics (FIND)  
Av. Budé 16  
1202 Geneva  
Switzerland  
[Catharina.boehme@finddiagnostics.org](mailto:Catharina.boehme@finddiagnostics.org)

**16. David Boyle**

PATH  
2201 Westlake Avenue  
Suite 200  
Seattle  
USA  
[dboyle@path.org](mailto:dboyle@path.org)

**17. Patricia Carlevaro**

OTSUKA SA  
Rue Mont Blanc 7  
Geneva  
Switzerland  
[pcarlevaro@otsuka-sa.ch](mailto:pcarlevaro@otsuka-sa.ch)

**18. Celia Carlos**

Research Institute for Tropical Medicine  
Filinvest Corporate City  
Alabang  
Muntinlupa  
Metro Manila  
Philippines  
[ccarlosph@yahoo.com](mailto:ccarlosph@yahoo.com)

**19. Martina Casenghi**

MSF  
Rue de Lausanne 78  
1201 Geneva  
Switzerland  
[martina.casenghi@geneva.msf.org](mailto:martina.casenghi@geneva.msf.org)

**20. Lucy Chesire**

Tuberculosis Advocacy Consortium  
Adalyn Court  
Suite C6  
Ngong Road  
Nairobi  
Kenya  
[lucy@tbadvocacy.org](mailto:lucy@tbadvocacy.org)

**21. Daniela Maria Cirillo**

HSR San Raffaele Scientific Institute  
Via Olgettina 58  
20132 Milan  
Italy  
[Cirillo.daniela@hsr.it](mailto:Cirillo.daniela@hsr.it)

**22. William Coggin**

Department of State / PEPFAR  
Office of the US Global AIDS Coordinator  
2100 Pennsylvania Ave NW  
Washington, 20522  
USA  
[cogginwl@state.gov](mailto:cogginwl@state.gov)

**23. Martin Colla**

Cepheid  
Vira Solelh, 81470 Maurens Scopont  
France  
[mcolla@cepheideurope.fr](mailto:mcolla@cepheideurope.fr)

**24. Christopher Coulter**

Queensland Mycobacterium Reference  
Laboratory  
Pathology Queensland  
Level 5, Block 7, Herston Hospitals Complex  
Butterfield St  
Herston QLD 4029  
Australia  
[Chris\\_Coulter@health.qld.gov.au](mailto:Chris_Coulter@health.qld.gov.au)

**25. Maria Alice da Silva Telles**

Senior Researcher  
GLI and MSH Laboratory Consultant  
Rua Cristiano Viana, 505/11  
São Paulo – SP 05411-001  
Brazil  
[atelles.msh@gmail.com](mailto:atelles.msh@gmail.com)

**26. Harkesh Dabas**

Clinton Health Access Initiative Inc  
F-79, Green Park Main  
New Delhi  
India  
[hdabas@clintonhealthaccess.org](mailto:hdabas@clintonhealthaccess.org)

**5th Annual Global Laboratory Initiative Meeting,  
Global Forum of Xpert MTB/RIF implementers, and  
Supranational TB Reference Laboratory Network Consultation**

**27. Charles Daley**

Head  
Division of Mycobacterial and Respiratory Infections  
National Jewish Medical and Research Center  
5301 Nassau Circle E  
80113 - Englewood, CO  
USA  
[daleyc@njhealth.org](mailto:daleyc@njhealth.org)

**28. Colleen Daniels**

Treatment Action Group  
261 Fifth Avenue, Suite 2110  
New York, NY 10016  
USA  
[colleen.daniels@treatmentactiongroup.org](mailto:colleen.daniels@treatmentactiongroup.org)

**29. Liliana Domete**

Institute of Phthisiopneumology  
Str. 13 Virnav  
Chisinau  
Republic of Moldova  
[ldomete@yahoo.com](mailto:ldomete@yahoo.com)

**30. Mao Tan Eang**

National Centre for Tuberculosis and Leprosy  
Control  
1, st. 278/95  
Boeung Keng Kang 2  
Chamkar Morn  
Phnom Penh  
Cambodia  
[mao@online.com.kh](mailto:mao@online.com.kh)

**31. Essam Elmoghazy**

Abdel Rasek Elsanhory st  
Nasr City, Cairo  
Egypt  
[elmoghazy@yahoo.com](mailto:elmoghazy@yahoo.com)

**32. Kathleen England**

Stanford University School of Medicine  
279 Campus Drive, Rm B237 Beckham Center  
Stanford University  
Stanford CA94305  
USA  
[englandk@stanford.edu](mailto:englandk@stanford.edu)

**33. Sara Eyangoh**

Centre Pasteur du Cameroun  
Rue Henri Dunan  
BP 1274  
Yaounde  
Cameroon  
[eyangoh@pasteur-yaounde.org](mailto:eyangoh@pasteur-yaounde.org)

**34. Bernard Fourie**

Department of Medical Microbiology  
University of Pretoria  
Pathology Building, 5 Bophelo Road  
Riveriera  
Pretoria 0089  
South Africa  
[Bernard.fourie@up.ac.za](mailto:Bernard.fourie@up.ac.za)

**35. Levan Gagnidze**

IOM Regional Office for Southeast Asia  
183 South Sathorn Road  
10120 Bangkok  
Thailand  
[lgagnidze@iom.int](mailto:lgagnidze@iom.int)

**36. David Hain**

Hain Lifescience  
Hardwiesenstrasse 1  
74147 Nehren  
Germany  
[david.hain@life-science.de](mailto:david.hain@life-science.de)

**37. Celestin Hakiruwizera**

American Society of Microbiology (ASLM)  
1752 N. Street, NW  
Washington, DC 20036  
USA  
[chakiruwizera@asmusa.org](mailto:chakiruwizera@asmusa.org)

**38. Rumina Hasan**

Aga Khan University  
Dept of Pathology and Microbiology  
Stadium Road  
PO Box 3500  
Karachi  
Pakistan  
[rumina.hasan@aku.edu](mailto:rumina.hasan@aku.edu)

**39. Harald Hoffmann**

Institute for Microbiology and Lab diagnostic  
Robert Koch-Allee 2  
Gauting  
Germany  
[Harald.Hoffmann@asklepios.com](mailto:Harald.Hoffmann@asklepios.com)

**40. Sven Hoffner**

Director of the WHO Supranational TB  
Reference Laboratory  
Department for Preparedness  
Swedish Institute for Communicable Disease  
Control  
Nobels väg 18, 171 86 Solna  
Sweden  
[sven.hoffner@smi.se](mailto:sven.hoffner@smi.se)

**5th Annual Global Laboratory Initiative Meeting,  
Global Forum of Xpert MTB/RIF implementers, and  
Supranational TB Reference Laboratory Network Consultation**

**41. Nguyen Van Hung**

National Lung Hospital  
463 Hoang Hoa Tham  
Ba Dinh  
Ha Noi  
Vet Nam  
[Hungmtb75@yahoo.co.uk](mailto:Hungmtb75@yahoo.co.uk)

**42. Michael F. Iademarco**

Chief, Laboratory Branch  
Division of Tuberculosis  
U.S. Centers for Disease Control and Prevention  
Mail Stop F-08, 1600 Clifton Road  
Atlanta, GA 30333  
USA  
[miademarco@cdc.gov](mailto:miademarco@cdc.gov)

**43. Nazir Ahmed Ismail**

NHLS  
National Institute of Communicable Diseases  
1 Modderfontein Road  
Sandringhom  
Johannesburg  
South Africa  
[naziri@nicd.ac.za](mailto:naziri@nicd.ac.za)

**44. Philippe Jacon**

Executive Vice President  
Cepheid Europe  
Vira-Solelh  
Maurens-Scopont  
France  
[Philippe.jacon@cepheid.com](mailto:Philippe.jacon@cepheid.com)

**45. Moses L. Joloba**

Department of Medical Microbiology  
Makerere University College of Health Sciences  
2<sup>nd</sup> Floor Pathology/Microbiology BL  
Room C31, Upper Mulago Hill Road  
256 Kampala  
Uganda  
[moses.joloba@case.edu](mailto:moses.joloba@case.edu)

**46. Gulmira Kalmambetova**

Head of NRL  
Bishkek  
Kyrgyzstan  
[gulmira.Kalmambetova@gmail.com](mailto:gulmira.Kalmambetova@gmail.com)

**47. Abebaw Kebede**

Ethiopian Health & Nutrition Research Institute  
(EHNRI)  
P.O Box 1242  
Addis Ababa  
Ethiopia  
[abesh\\_k@yahoo.com](mailto:abesh_k@yahoo.com)

**48. Salmaan Keshavjee**

Harvard Medical School  
641 Huntington Avenue  
Boston, MA 02115  
USA  
[Salmaan.Keshavjee@hms.harvard.edu](mailto:Salmaan.Keshavjee@hms.harvard.edu)

**49. Aamir Khan**

Interactive Research and Development (IDR)  
Suite 508, Ibrahim Trade Tower  
Main Sharah-E.Faisal  
Karachi  
Pakistan  
[Aamir.khan@irdresearch.org](mailto:Aamir.khan@irdresearch.org)

**50. Kekeletso Kao**

FIND  
16 Avenue de Bude  
Geneva  
Switzerland  
[Kekeltso.kao@finddiagnostics.org](mailto:Kekeltso.kao@finddiagnostics.org)

**51. Chang Ki Kim**

The Korean Institute of Tuberculosis  
168-5, Osongsaengmyeong 4-ro  
Osong-eup  
Cheongwon-gun  
Chungcheongbuk-do,  
Korea  
[pssoas95@gmail.com](mailto:pssoas95@gmail.com)

**52. Alexei Korobitsyn**

FIND  
16 Avenue de Bude  
Geneva  
Switzerland  
[alexei.korobitsyn@gmail.com](mailto:alexei.korobitsyn@gmail.com)

**53. Ivor Langley**

Liverpool School of Tropical Medicine  
Pembroke Place  
Liverpool L3 5QA  
United Kingdom  
[ivor.langley@liv.ac.uk](mailto:ivor.langley@liv.ac.uk)

**54. Troels Lillebaek**

Statens Serum Institut  
5 Artillerivej  
DK-2300  
Copenhagen  
[tll@ssi.dk](mailto:tll@ssi.dk)

**5th Annual Global Laboratory Initiative Meeting,  
Global Forum of Xpert MTB/RIF implementers, and  
Supranational TB Reference Laboratory Network Consultation**

**55. Christophe Longuet**

Fondation Mérieux  
55 route d'Annecy  
74290 Veyrier-du-Lac  
France  
[Christophe.longuet@fondation-merieux.org](mailto:Christophe.longuet@fondation-merieux.org)

**56. Beatriz Lopez**

INEI  
Avenue Velez Sarsfield 563  
Buenos Aires  
Argentina  
[bealopez@anlis.gov.ar](mailto:bealopez@anlis.gov.ar)

**57. D.K W. Lwamafa**

Ministry of Health  
P.O Box 7272  
Kampala  
Uganda  
[lwamafa@hotmail.com](mailto:lwamafa@hotmail.com)

**58. Paolo Maggiore**

Clinton Health Access Initiative  
282 Dorchester Avenue  
Boston  
USA  
[pmaggiore@clintonhealthaccess.org](mailto:pmaggiore@clintonhealthaccess.org)

**59. Andrey Olegorich Maryandyshev**

Chair, GLC\Europe  
Head of the Phthisiopulmonology Department  
Northern State Medical University,  
Troitsky 51,  
163061 - Arkhangelsk  
Russian Federation  
[maryandyshev@mail.ru](mailto:maryandyshev@mail.ru)

**60. Alain Mérieux**

Fondation Mérieux  
17 rue Bourgelat  
69002 Lyon  
France  
[fondation.lyon@fondation-merieux.org](mailto:fondation.lyon@fondation-merieux.org)

**61. Satoshi Mitarai.**

Head, Bacteriology  
Department of Mycobacterium Reference and  
Research,  
Research Institute of Tuberculosis  
Japan Anti-Tuberculosis Association  
3-1-24 Matsuyama, Kiyose,  
Tokyo 204-8533  
Japan  
[mitarai@jata.or.jp](mailto:mitarai@jata.or.jp)

**62. Andrei Mosneaga**

PAS Center  
Director, Programs Management  
32 Bulgara Street  
Chisinau MD-2001  
Moldova  
[andrei.mosneaga@pas.md](mailto:andrei.mosneaga@pas.md)

**63. Frank Rwabinumi Mugabe**

Programme Manager  
National TB and Leprosy Programme  
PO Box 16069  
Kampala  
Uganda  
[drfmugabe@yahoo.com.au](mailto:drfmugabe@yahoo.com.au)

**64. Catherine Mundy**

Management Sciences for Health (MSH)  
4301 N Fairfax Drive, Suite 400  
Arlington, VA22203  
USA  
[cmundy@msh.org](mailto:cmundy@msh.org)

**65. Gulnora Murmusaeva**

Republican Specialized Scientific and Practical  
Medical Center of Phthisiology and  
Pulmonology  
Building 1, Alimova st  
Tashkent  
Uzbekistan  
[m-gulnora61@mail.ru](mailto:m-gulnora61@mail.ru)

**66. Obadiah Njuguna**

Ministry of Health  
PO Box 30016  
Nairobi  
Kenya  
[njugunaobadiah@yahoo.com](mailto:njugunaobadiah@yahoo.com)

**67. Wint Wint Nyunt**

Microbiologist  
National TB Reference Laboratory  
No. 12 Kyankin Street  
Sanchaung  
Yangon  
Myanmar  
[wintwintnyunt@gmail.com](mailto:wintwintnyunt@gmail.com)

**68. Richard O'Brien**

P.O Box 2938  
Frisco, CO 80443  
USA  
[RJOBRIEN1@gmail.com](mailto:RJOBRIEN1@gmail.com)

**5th Annual Global Laboratory Initiative Meeting,  
Global Forum of Xpert MTB/RIF implementers, and  
Supranational TB Reference Laboratory Network Consultation**

**69. Jeremiah Okari**

Ministry of Health  
PO Box 30016  
Nairobi  
Kenya  
[jeergoo@gmail.com](mailto:jeergoo@gmail.com)

**70. Daniel Orozco**

Project Manager EXPANDx-TB  
FIND/GLI  
Avenue de Budé 16  
Geneva 1202  
Switzerland  
[daniel.orozco@finddiagnostics.org](mailto:daniel.orozco@finddiagnostics.org)

**71. Linda Oskam**

KIT Biomedical Research,  
Royal Tropical Institute  
Meibergdreef 39  
1105 AZ Amsterdam  
The Netherlands  
[l.oskam@kit.nl](mailto:l.oskam@kit.nl)

**72. C.N Paramasivan**

Foundation for Innovative New Diagnostics (FIND)  
14 D & E Hansalaya Building  
15 Barakhamba Road  
New Delhi – 110001  
India  
[cn.paramasivan@finddiagnostics.org](mailto:cn.paramasivan@finddiagnostics.org)

**73. Sok Heng Pheng**

National Centre for Tuberculosis and Leprosy  
Control  
1, st. 278/95  
Boeung Keng Kang 2  
Chamkar Morn  
Phnom Penh  
Cambodia  
[sokhengpheng@yahoo.com](mailto:sokhengpheng@yahoo.com)

**74. Andrea Pantoja**

Ankenhofstrasse 23  
8102 Oberengstringen  
Switzerland  
[andreagpantoja@gmail.com](mailto:andreagpantoja@gmail.com)

**75. Mark Perkins**

Foundation for Innovative New Diagnostics (FIND)  
16 Avenue de Budé  
Geneva  
Switzerland  
[mark.perkins@finddiagnostics.org](mailto:mark.perkins@finddiagnostics.org)

**76. Amy Piatek**

USAID/BGH/HIDN/ID  
US Agency for International Development  
(USAID)  
Ronald Reagan Building  
Washington  
USA  
[apiatek@usaid.gov](mailto:apiatek@usaid.gov)

**77. Valentina Picot**

Fondation Mérieux  
55 route d'Annecy  
74290 Veyrier-du-Lac  
France  
[valentina.picot@fondation-merieux.org](mailto:valentina.picot@fondation-merieux.org)

**78. Florence Pradel**

Fondation Mérieux  
55 route d'Annecy  
74290 Veyrier-du-Lac  
France

**79. Romain Prieur**

Cepheid  
904 Caribbean Drive  
Sunnyvale CA 94089  
USA  
[romain.prieur@cepheid.com](mailto:romain.prieur@cepheid.com)

**80. Manuela Rehr**

PMU/TB CARE I / KNCV  
Parkstraat 17  
2514 JD The Hague  
Netherlands  
[rehrm@kncvtbc.nl](mailto:rehrm@kncvtbc.nl)

**81. Lee Reichman**

NJMS Global TB Institute  
225 Warren Street  
Box 1709  
Newark  
NJ 07101-1709  
USA  
[reichmlb@umdnj.edu](mailto:reichmlb@umdnj.edu)

**82. Michael Rich**

Partners in Health  
Harvard Medical School  
641 Huntington Avenue  
Boston  
USA  
[mrich@pih.org](mailto:mrich@pih.org)

**5th Annual Global Laboratory Initiative Meeting,  
Global Forum of Xpert MTB/RIF implementers, and  
Supranational TB Reference Laboratory Network Consultation**

**83. Dhanida Rienthong**

NRL & SRL of Tuberculosis  
116 Sudprasert Rd, Bangkhlo, Bangkorlaem  
Bangkok 10120  
Thailand  
[dhanida2547@yahoo.com](mailto:dhanida2547@yahoo.com)

**84. John Ridderhof**

Centers for Disease Control and Prevention  
1600 Clifton Road  
MS E94  
Atlanta  
USA  
[jridderhof@cdc.gov](mailto:jridderhof@cdc.gov)

**85. Marc Rodriguez**

Fondation Mérieux  
55 route d'Annecy  
74290 Veyrier-du-Lac  
France  
[marc.rodriquez@foundation-merieux.org](mailto:marc.rodriquez@foundation-merieux.org)

**86. Sabine Rüsç-Gerdes**

Head  
National Reference Center for Mycobacteria  
Forschungszentrum Borstel  
Parkallee 18  
23845 – Borstel  
Germany  
[srueschg@fz-borstel.de](mailto:srueschg@fz-borstel.de)

**87. Max Salfinger**

National Jewish Health  
1400 Jackson Street  
Denver  
Colorado 80206  
USA  
[salfingerm@njhealth.org](mailto:salfingerm@njhealth.org)

**88. Hind Satti**

Partners In Health  
Private Bag A391  
Lesotho  
[hsatti@pih.org](mailto:hsatti@pih.org)

**89. Jerod N. Scholten**

Senior Consultant  
KNCV Tuberculosis Foundation  
Parkstraat 17  
2514 JD The Hague  
The Netherlands  
[ScholtenJ@kncvtbc.nl](mailto:ScholtenJ@kncvtbc.nl)

**90. Lesley Scott**

Wits University  
National Health Laboratory Services  
Wits Medical School  
7 York Road  
Parktown, Johannesburg  
South Africa  
[Lesley.Scott@nhls.ac.za](mailto:Lesley.Scott@nhls.ac.za)

**91. Thomas M Shinnick**

U.S. Centers for Disease Control and Prevention  
1600 Clifton Rd NE  
Atlanta GA 30333  
USA  
[tms1@cdc.gov](mailto:tms1@cdc.gov)

**92. Amelia Vanda Siagian**

National Tuberculosis Program Indonesia  
Jalan Percetakan Negara No. 29  
Jakarta 10560  
Indonesia  
[vanda\\_siagian@yahoo.com](mailto:vanda_siagian@yahoo.com)

**93. Alena Skrahina**

Deputy Director  
Republican Research and Practical Centre  
for Pulmonology and Tuberculosis  
Dolginovski Trakt 157  
220053 Minsk  
Belarus  
[alena\\_skrahina@tut.by](mailto:alena_skrahina@tut.by)

**94. Bertie Squire**

Liverpool School of Tropical Medicine  
Pembroke Place  
Liverpool, L3 5QA  
UK  
[sbsquire@liv.ac.uk](mailto:sbsquire@liv.ac.uk)

**95. Wendy Stevens**

Wits University  
National Health Laboratory Services  
Wits Medical School  
7 York Road  
Parktown, Johannesburg  
South Africa  
[wendy.stevens@nhls.ac.za](mailto:wendy.stevens@nhls.ac.za)

**96. Jan Steuperaert**

Cepheid  
Vira-Solelh, F-81470 Maurens-Scopont  
France  
[Jan.steuperaert@cepheid.com](mailto:Jan.steuperaert@cepheid.com)

**5th Annual Global Laboratory Initiative Meeting,  
Global Forum of Xpert MTB/RIF implementers, and  
Supranational TB Reference Laboratory Network Consultation**

**97. Thynn Lei Swe**

Microbiologist  
Regional TB Control Programme  
Myanmar  
[thynleiswe@gmail.com](mailto:thynleiswe@gmail.com)

**98. Jeff Takle**

Abt Associates  
55 Wheeler Street  
Cambridge  
MA 02138  
USA  
[Jeff\\_table@abtassociates.com](mailto:Jeff_table@abtassociates.com)

**99. Sabira Tahseen**

National TB Reference Laboratory  
National Tuberculosis Programme  
PIMS Satellite Hospital  
Chak Shahzada  
Islamabad  
Pakistan  
[sabira.tahseen@gmail.com](mailto:sabira.tahseen@gmail.com)

**100. Martie van der Walt**

TB Epidemiology and Intervention Research Unit  
South African Medical Research Council  
Private Bag X385  
Pretoria 0001  
South Africa  
[vdwalt@mrc.ac.za](mailto:vdwalt@mrc.ac.za)

**101. Maarten van Cleeff**

KNCV Tuberculosis Foundation  
Parkstraat 17  
2514 JD The Hague  
The Netherlands  
[vancleeffm@kncvtbc.nl](mailto:vancleeffm@kncvtbc.nl)

**102. Armand Van Deun**

The Union  
Institute of Tropical Medicine  
Nationalestraat 155  
2000 Antwerpen  
Belgium  
[avandeun@theunion.org](mailto:avandeun@theunion.org)

**103. Sanne van Kampen**

KNCV Tuberculosis Foundation  
Parkstraat 17  
2514 JD, The Hague  
The Netherlands  
[vankampens@kncvtbc.nl](mailto:vankampens@kncvtbc.nl)

**104. Sofia Viegas**

Head of the National Reference Laboratory  
Ministry of Health  
Maputo  
Mozambique  
[viegas\\_sofia@hotmail.com](mailto:viegas_sofia@hotmail.com)

**105. Eliud Wandwalu**

The Global Fund to fight AIDS, TB and Malaria  
Geneva  
Switzerland  
[Eliud.Wandwalu@theglobalfund.org](mailto:Eliud.Wandwalu@theglobalfund.org)

**106. Jesse Wambugu**

FIND  
16 Avenue de Bude  
Geneva  
Switzerland  
[Jesse.wambugu@finddiagnostics.org](mailto:Jesse.wambugu@finddiagnostics.org)

**107. William Wells**

TB Alliance  
40 Wall Street  
24<sup>th</sup> Floor, New York  
NY 10005  
USA  
[William.wells@tballiance.org](mailto:William.wells@tballiance.org)

**108. Aksana Zalutskaya**

Republican Scientific and Practical Center for  
Pulmonology and Tuberculosis  
Dolginovsky tract 157  
220053 Minsk  
Belarus  
[akasana@inbox.ru](mailto:akasana@inbox.ru)

**109. Yanlin Zhao**

Chinese Center for Disease Control and  
Prevention  
No 155 ChangBai Road  
Changping District  
Beijing  
102206  
P.R China  
[zhaoyanlin@chinatb.org](mailto:zhaoyanlin@chinatb.org)

**World Health Organization  
Regional/Country offices**

**110. Samiha Baghdadi**

Medical Officer  
EMRO  
[baghdadis@who.int](mailto:baghdadis@who.int)

**111. Md Khurshid Alam Hyder**

Regional Adviser-TB  
SEARO  
[hyderk@searo.who.int](mailto:hyderk@searo.who.int)



**5th Annual Global Laboratory Initiative Meeting,  
Global Forum of Xpert MTB/RIF implementers, and  
Supranational TB Reference Laboratory Network Consultation**

**112. Daniel Kibuga**

Medical Officer  
AFRO  
[kibugad@who.int](mailto:kibugad@who.int)

**113. Kristin Kremer**

Medical Officer  
EURO  
[kkremer@euro.who.int](mailto:kkremer@euro.who.int)

**114. Ranjani Ramachandran**

Medical Officer  
SEARO  
[ramachandranr@searo.who.int](mailto:ramachandranr@searo.who.int)

**115. Sabera Sultana**

National Professional Officer, DR/TB  
Bangladesh Country Office  
[sultanas@searo.who.int](mailto:sultanas@searo.who.int)

**116. Tauhid Islam**

Medical Officer  
WPRO  
[islamt@wpro.who.int](mailto:islamt@wpro.who.int)

**117. Anna Volz**

Medical Officer  
AMRO  
[volza@paho.org](mailto:volza@paho.org)

**Headquarters**

**Stop TB Department (STB)**

**118. Mario Raviglione**

[raviglionem@who.int](mailto:raviglionem@who.int)

**STB/LDR**

**119. Karin Weyer**

[weyerk@who.int](mailto:weyerk@who.int)

**120. Vineet Bhatia**

[bhatiav@who.int](mailto:bhatiav@who.int)

**121. Dennis Falzon**

[falzond@who.int](mailto:falzond@who.int)

**122. Chris Gilpin**

[gilpinc@who.int](mailto:gilpinc@who.int)

**123. Henrikka Huttunen**

[huttunen@who.int](mailto:huttunen@who.int)

**124. Jean Iragena**

[iragenaj@who.int](mailto:iragenaj@who.int)

**125. Fuad Mirzayev**

[mirzayevf@who.int](mailto:mirzayevf@who.int)

**126. Wayne van Gemert**

[vangemertw@who.int](mailto:vangemertw@who.int)

**127. Fraser Wares**

[waresf@who.int](mailto:waresf@who.int)

**STB/PSI**

**128. Christian Lienhardt**

[lienhardtc@who.int](mailto:lienhardtc@who.int)

**129. Knut Lonnoth**

[lonnothk@who.int](mailto:lonnothk@who.int)

**STB/TME**

**130. Matteo Zignol**

[zignolm@who.int](mailto:zignolm@who.int)

**STB/TSC**

**131. Malgosia Grzemska**

[grzemska@who.int](mailto:grzemska@who.int)

**Stop TB Partnership (TBP)**

**132. Lucica Ditiu**

[ditiul@who.int](mailto:ditiul@who.int)

**133. Jacob Creswell**

[creswellj@who.int](mailto:creswellj@who.int)

**134. Suvanand Sahu**

[sahus@who.int](mailto:sahus@who.int)

**135. Thomas Verges**

[vergest@who.int](mailto:vergest@who.int)

**UNITAID**

**136. Janet Ginnard**

WHO/UNITAID  
[ginnardj@who.int](mailto:ginnardj@who.int)

**137. Robert Matiru**

WHO/UNITAID  
[matirur@who.int](mailto:matirur@who.int)

**138. Yamuna Mundade**

WHO/UNITAID  
[mundadey@who.int](mailto:mundadey@who.int)